文献速递姑息放疗与转移瘤放疗物理与技术

总剂量、分次剂量与呼吸运动管理对肾上腺立体定向放疗结局的影响

Total dose, fraction dose and respiratory motion management impact adrenal SBRT outcome.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-05-04

该研究回顾性分析了以色列某医疗中心2015至2021年83例肾上腺转移瘤立体定向放疗病例,评估局部控制与生存相关因素。多因素分析显示生物有效剂量>75 Gy、分次剂量>8 Gy以及屏气或持续气道正压通气与局部控制显著相关。作者认为单侧肾上腺立体定向放疗安全,但双侧治疗存在肾上腺功能不全风险,并提出列线图辅助决策。

要点

  • 生物有效剂量>75 Gy与局部控制显著相关(HR=0.41,p=0.031)。
  • 分次剂量>8 Gy与局部控制显著相关(HR=0.53,p=0.038)。
  • 屏气或持续气道正压通气与局部控制显著相关(HR=0.65,p=0.047)。

核心结论

  • 作者认为单侧肾上腺立体定向放疗安全,但双侧治疗存在肾上腺功能不全风险。
  • 生物有效剂量>75 Gy、分次剂量>8 Gy以及屏气或持续气道正压通气是改善局部控制的因素。
  • 作者提出列线图以辅助肾上腺立体定向放疗时总剂量和分次剂量的决策。

研究设计与样本

  • 经机构审查委员会批准后,对以色列某医疗中心2015至2021年接受肾上腺转移瘤立体定向放疗的患者进行回顾性数据回顾。
  • 采用α/β比值为10计算生物有效剂量,使用SPSS软件进行Kaplan-Meier分析和Cox回归分析,描述局部控制和生存的风险比。

主要发现

  • 共识别83例肾上腺立体定向放疗病例,平均年龄67岁(范围42-92岁)。
  • 非小细胞肺癌为原发部位者占44%,70%的患者为寡转移性疾病(少于五个病灶),其余为多转移性疾病、对全身治疗有反应且肾上腺出现寡进展。
  • 平均大体肿瘤体积为42 ml。
  • 88%的病例应用了呼吸控制,其中49.3%使用4-D/ITV,38.5%使用屏气或持续气道正压通气联合自由呼吸。
  • 多因素分析显示,生物有效剂量>75 Gy(HR=0.41,p=0.031)、分次剂量>8 Gy(HR=0.53,p=0.038)以及屏气或持续气道正压通气(HR=0.65,p=0.047)与局部控制显著相关。

关键数值与推荐

  • 生物有效剂量>75 Gy:HR=0.41,p=0.031。
  • 分次剂量>8 Gy:HR=0.53,p=0.038。
  • 屏气或持续气道正压通气:HR=0.65,p=0.047。
  • 利用七个临床参数计算预测列线图曲线以评估局部控制概率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVES: Stereotactic body radiotherapy (SBRT) is an effective treatment for oligometastatic disease in multiple sites. However, the optimal radiation dose for long-term local control of adrenal metastases has yet to be determined. The aim of this study is to evaluate outcomes of adrenal SBRT and to evaluate factors that correlate with local control. MATERIALS/METHODS: After IRB approval, a retrospective data review of patients treated with SBRT for adrenal metastases at a medical center in Israel between 2015 and 2021 was conducted. A biological effective dose was calculated using an alpha beta ratio of 10. Kaplan Meier and Cox regression were calculated using SPSS software to describe the hazard ratio for local control and survival. RESULTS: 83 cases of adrenal SBRT were identified. The average age was 67 (range 42-92 years old). Non-small cell lung cancer was the primary site in 44 % of patients. A total of 70 % of the patients had oligometastatic disease (less than five lesions), and the rest were polymetastatic, responding to systemic therapy with oligo progression in the adrenal. The average gross tumor volume (GTV) was 42 ml. Respiratory control was applied in 88 % of cases; 49.3 % used 4-D/ITV, and 38.5 % used breath-hold or continuous positive airway pressure (CPAP) with free breathing. On multivariable analysis, Dose above 75 Gy (biological effective Dose) (HR = 0.41, p = 0.031), Dose above 8 Gy per fraction (HR = 0.53p = 0.038), and breath-holds or CPAP (HR = 0.65, p = 0.047) were significant for local control. From multivariable analysis, we computed a predicted nomogram curve using seven clinical parameters to evaluate local control odds. CONCLUSION: In this single institution series reported to date, we found unilateral adrenal SBRT safe, yet bilateral treatment harbors a risk of adrenal insufficiency. Biological effective Dose > 75 Gy (BED), motion management with breath-hold or CPAP, and Dose per fraction > 8 Gy were the enhanced local controls. We propose a nomogram to help in decision-making regarding total Dose and Dose per fraction when treating adrenal SBRT.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Haisraely O, Weiss I, Jaffe M, et al. Total dose, fraction dose and respiratory motion management impact adrenal SBRT outcome. Clin Transl Radiat Oncol. 2024. PMID: 38745963. doi:10.1016/j.ctro.2024.100788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。